Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$9.55 USD
-0.08 (-0.83%)
Updated Apr 30, 2024 03:59 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALPMY 9.55 -0.08(-0.83%)
Will ALPMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
New Strong Sell Stocks for October 2nd
New Strong Sell Stocks for September 26th
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for September18th
New Strong Sell Stocks for August 21st
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
Other News for ALPMY
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance
Warning: ALPMY is at high risk of performing badly
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Takeda, Astellas and Sumitomo to create new drug discovery company